About Developmental pluripotency-associated protein 4
Developmental pluripotency-associated protein 4 (DPPA4) is a protein
from Homo sapiens identified by UniProt accession
Q7L190, 304 residues long.
MolForge cross-references it against 0 known binders and
32 disease associations.
Target properties
| Protein name | Developmental pluripotency-associated protein 4 |
|---|
| UniProt accession | Q7L190 |
|---|
| Gene | DPPA4 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 304 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (32)
Diseases linked to this target (Open Targets).
- adolescent idiopathic scoliosis · score 0.27
- cutaneous melanoma · score 0.15
- Familial prostate cancer · score 0.11
- prostate carcinoma · score 0.11
- prostate cancer · score 0.11
- lung adenocarcinoma · score 0.10
- non-small cell lung carcinoma · score 0.08
- neoplasm · score 0.05
- cancer · score 0.05
- short-rib thoracic dysplasia 17 with or without polydactyly · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q7L190-F1 | alphafold | PREDICTED | 65.41 | — |
Amino-acid sequence (304 residues)
MLRGSASSTS MEKAKGKEWT STEKSREEDQ QASNQPNSIA LPGTSAKRTK EKMSIKGSKV LCPKKKAEHT DNPRPQKKIP IPPLPSKLPP VNLIHRDILR AWCQQLKLSS KGQKLDAYKR LCAFAYPNQK DFPSTAKEAK IRKSLQKKLK VEKGETSLQS SETHPPEVAL PPVGEPPALE NSTALLEGVN TVVVTTSAPE ALLASWARIS ARARTPEAVE SPQEASGVRW CVVHGKSLPA DTDGWVHLQF HAGQAWVPEK QEGRVSALFL LPASNFPPPH LEDNMLCPKC VHRNKVLIKS LQWE
Explore Developmental pluripotency-associated protein 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets